Halozyme Therapeutics Inc. Common Stock vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $109.92 (market cap $12.58B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.61 (market cap $330.98M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 38× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| HALO | XDTE | |
|---|---|---|
Market Cap | $12.58B | $330.98M |
Volume | 2,179,278 | 194,030 |
Sector | Health | Income / Options Overlay |
52-Week High | $115.22 | $44.76 |
52-Week Low | $61.63 | $36.00 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $14.49B | — |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →